15
Sep

Two years after safety concerns torpedoed their first pitch, partners Baxter and Halozyme Therapeutics have locked up FDA approval for HyQvia, a treatment for immunodeficiency.

…read more

Source: Baxter and Halozyme sway the FDA after a painful rejection

    

0 No comments